Abstract: Objectives: The overall prevalence of hypertension (HTN) among Israeli Jewish adolescents was reported to be 0.4% in males and 0.074% in females. The demographic characteristics of Northern Israeli population are unique, with a nearly equal distribution of Arab and Jewish ethnicity. We describe the demographic and clinical characteristics of pediatric hypertensive patients in northern Israel. Design: Data was retrospectively collected from electronic medical records (EMR) of pediatric patients aged 0-18 diagnosed with HTN at Rambam Health Care Campus between 2010-2020. Demographic characteristics, etiology, end-organ damage (EOD), and medical treatment were collected and compared between specific subgroups. Results: During the study period, 479 children diagnosed with HTN were included. Mean age at diagnosis was 9.6 years. 64% were males. BMI > 85th percentile was measured in 45%. 17% were diagnosed with primary HTN. Primary HTN was more prevalent (32%) in adolescents, the majority of Jewish ancestry. Obesity prevalence was significantly higher in primary HTN patients. EOD was more common in secondary HTN, Arab-Muslim origin, consanguinity, and younger age. At follow-up, 35.8% were without antihypertensive medications. Calcium channel blockers were the most frequently prescribed anti-hypertensives. Conclusions: Higher rates of secondary HTN than reported in the literature were attributed to high consanguinity and resulted in extensive diagnostic procedures across all age groups, unlike AAP guidelines recommendations. Better adherence to guideline recommendations was demonstrated in patients referred to the pediatric nephrology institute, highlighting the importance of referral of HTN patients to specialized clinics.

The authors have declared no competing interest.

Rambam Health Care Campus Helsinki committee number 0127-21

no funding was received

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Not Applicable

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

by Rambam Health Care Campus Helsinki committee number 0127-21

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Not Applicable

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Not Applicable

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Not Applicable

All data generated or analyzed during this study are included in this published article, more data that support the findings of this study are available from the corresponding author upon reasonable request.